BioNTech reported fourth quarter and full year 2025 results, updated 2026 guidance and outlined a major oncology-focused strategy shift. 2025 revenues were €2.9 billion while the company recorded a net loss of €1.1 billion and adjusted net loss of €0.1 billion. Cash, cash equivalents and security investments totaled €17.2 billion, providing substantial funding for its expanding cancer pipeline.
For 2026, BioNTech expects total revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion and adjusted SG&A expenses of €700–800 million as it prioritizes late‑stage oncology development. Management highlighted multiple 2026 data readouts across immunomodulators, antibody‑drug conjugates and mRNA cancer immunotherapies.
The company plans an independent next‑generation mRNA venture to be led by co‑founders Ugur Sahin and Özlem Türeci, who are expected to transition by the end of 2026. BioNTech aims to become a multi‑product oncology company by 2030 with numerous planned late‑stage and potentially registrational trials.
BioNTech SE plans to support the creation of an independent biotechnology company led by co-founders Prof. Ugur Sahin and Prof. Özlem Türeci that will focus on next-generation mRNA innovations. BioNTech intends to contribute related rights and mRNA technologies in return for a minority stake, milestones and royalties.
BioNTech says its current clinical pipeline, including its COVID‑19 vaccine franchise, remains unaffected and expects to have 15 ongoing Phase 3 oncology trials by year end, with multiple late-stage data readouts in 2026. Sahin and Türeci are expected to transition to the new company’s management by the end of 2026, while BioNTech’s Supervisory Board has started searching for their successors.
BioNTech SE insider Ugur Sahin has filed a Form 144 indicating an intent to sell 858,209 American Depositary Shares (ADS), representing ordinary shares with no par value. The planned sale through Berenberg Capital Markets LLC on the Nasdaq Global Select Market has an aggregate market value of $93,870,900.42, while 240,455,450 ADS were outstanding.
The securities to be sold were acquired via stock option exercises on 11/21/2022 (856,186 ordinary shares) and 08/09/2024 (2,023 ordinary shares). Over the past three months, Sahin has already sold multiple ADS blocks, including 72,970 ADS for $7,901,797.25 on 01/14/2026 and 62,000 ADS for $7,451,792.40 on 01/22/2026.
BioNTech SE announced that its Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer, effective March 1, 2026. This is a newly created role focused on leading the company’s global people strategy.
The appointment supports BioNTech’s strategy to evolve into a multi-product oncology company by 2030, emphasizing the importance of its global, highly skilled workforce. Jimenez brings more than 20 years of international HR experience from Georg Fischer, Toyota, Johnson & Johnson, and General Mills, and will be based at BioNTech’s headquarters in Mainz, Germany.
BioNTech SE submitted a report describing a strategic business update delivered at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. On January 13, 2026, the company outlined its focus areas for 2026 and provided an overview of expected near- to longer-term milestones. The related presentation is made available as Exhibit 99.1 to this report.
BioNTech SE is using a 2026 strategic update to highlight its shift toward becoming a multi-product oncology company while relying on its COVID-19 franchise and strong balance sheet. The company expects seven late-stage oncology data readouts in 2026 and plans to have 15 Phase 3 clinical trials ongoing by year-end, across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. By 2030+, BioNTech anticipates at least 17 late-stage or pivotal data readouts that could support multiple product launches in major tumors such as lung, breast, gynecologic and head and neck cancers.
Financially, BioNTech reported approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025 and in November 2025 raised its 2025 revenue guidance to €2.6–2.8 billion while lowering expense guidance ranges. For 2026, it anticipates a modest decline in Comirnaty revenues and does not expect to recognize revenues from oncology product sales, while revenues from its Bristol Myers Squibb collaboration are expected to be broadly in line with 2025.
BioNTech SE reports that it has completed its exchange offer for all outstanding shares of CureVac N.V., following the expiration of the subsequent offering period. This means CureVac is now being acquired by BioNTech through a share-exchange structure rather than a cash-only deal. The company states that this step closes the acquisition process and is intended to strengthen BioNTech’s position in the mRNA field. The press release describing the transaction is included as an exhibit and this report is incorporated by reference into BioNTech’s existing Form F-4 registration statement.
BioNTech SE submitted a Form 6-K reporting that it issued a press release on November 26, 2025 about its exchange offer for all outstanding shares of CureVac N.V.. The press release announces the results of CureVac’s extraordinary general meeting and the calculation of the exchange ratio for the offer.
The filing states that this Form 6-K is incorporated by reference into BioNTech’s Form F-4 registration statement. The attached press release, filed as Exhibit 99.1, highlights progress on the exchange offer and notes a December 3, 2025 at 9:00 a.m. Eastern Time expiration for the offer.
BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.
The related presentation is attached as Exhibit 99.1. The filing is signed by Chief Financial Officer Ramon Zapata‑Gomez and Chief Operating Officer Dr. Sierk Poetting.
BioNTech SE submitted a Form 6‑K as a foreign private issuer to provide investors with a development update and its latest financial information. On November 3, 2025, the company reported its financial results for the three and nine months ended September 30, 2025, and prepared interim condensed consolidated financial statements for that period. These financial statements, along with an operating and financial review and prospects section, are included as Exhibit 99.1 to the report and are deemed filed under the Securities Exchange Act. The filing is signed on behalf of BioNTech SE by its Chief Financial Officer and Chief Operating Officer.